Oct
2026
Fiera Milano, Italy
Visit us
stand 12P26, Contract Manufacturing & Services

PolyPeptide Group

Exhibitor at CPHI Milan 2026
About Us

PolyPeptide Group is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Sweden
  • On CPHI since:
    2015
  • Employees:
    1000 - 4999
Company types
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Cosmetic Ingredients
Custom Manufacturing/Custom Synthesis
Generic APIs producer
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 12P26, Contract Manufacturing & Services

Products Featured at CPHI Milan 2026

  • PTH (1-34) / Teriparatide

    Product PTH (1-34) / Teriparatide

    Human Parathyroid Hormone (1-34) is used for treatment of osteoporosis in postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who have a high risk of bone fracture.
  • Desmopressin

    Product Desmopressin

    Desmopressin is an analogue of the human antidiuretic hormone, vasopressin. It mimics the action of vasopressin on the kidneys to increase the reabsorption of water thereby reducing the volume of urine produced. Desmopressin is a synthetic cyclic nonapeptide, available as the acetate.
  • Triptorelin

    Product Triptorelin

    Triptorelin is an analogue of Gonadorelin with a slower degradation than the natural hormone and exhibiting superagonist properties. It is used for the treatment of malignant neoplasm of the prostate as well as for treatment of infertility and other sex hormone-related conditions.
  • Leuprolide

    Product Leuprolide

    Leuprolide Acetate is an analogue of Gonadorelin with similar properties. It is used for the treatment of prostate cancer. Furthermore, it is used for the treatment of central precocious puberty and in the management of endometriosis.
  • Octreotide

    Product Octreotide

    Octreotide Acetate is an octapeptide analogue of somatostatin with similar properties, but with a longer duration of action. The product is offered in countries where the patents have expired.